10 Percent of Heart Recipients Develop De Novo Malignancy

Share this content:
10 Percent of Heart Recipients Develop De Novo Malignancy
10 Percent of Heart Recipients Develop De Novo Malignancy

TUESDAY, Jan. 2, 2018 (HealthDay News) -- More than one in 10 adult heart transplant recipients develop de novo malignancy between one and five years after transplantation, and this is associated with increased mortality, according to a study published in the Jan. 2 issue of the Journal of the American College of Cardiology.

Jong-Chan Youn, M.D., Ph.D., from the Hallym University College of Medicine in Hwaseong, South Korea, and colleagues examined temporal trends of post-transplant incidence, types, and predictors of malignancy using data for 17,587 primary adult heart-only transplant recipients from the International Society for Heart and Lung Transplantation registry.

The researchers found that the risk of developing any de novo solid malignancy was 10.7 percent between one and five years after transplantation. By malignancy type, the cumulative incidence was 7, 4, and 0.9 percent for skin cancer, non-skin solid cancer, and lymphoproliferative disorders, respectively. No temporal difference was seen in the time to development according to malignancy type. From 2000-2005 to 2006-2011, the cumulative incidence of de novo solid malignancy increased from 10 to 12.4 percent (P < 0.0001). Markedly lower survival was seen for patients after de novo malignancy versus no malignancy (P < 0.0001). The risk of de novo malignancy was higher for older recipients and patients who underwent transplantation in the recent era.

"Individualized immunosuppression strategies and enhanced cancer screening should be studied to determine whether they can reduce the adverse outcomes of post-transplantation malignancy," the authors write.

Two authors disclosed financial ties to the medical device and pharmaceutical industries.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Jury Awards 4.62B in Johnson  Johnson Talcum Powder Lawsuit

Jury Awards &#36;4.62B in Johnson &amp; Johnson Talcum ...

The award includes $550 million in compensatory damages and $4.14 billion in punitive damages

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

100 Now Sickened by Salmonella-Tainted Honey Smacks Cereal

Thirty people have been hospitalized, but no deaths have been reported

Data Support FDA Restrictions on Child Cough and Cold Medicines

Data Support FDA Restrictions on Child Cough and ...

Surveillance data showed more adverse events for children exposed to hydrocodone than codeine

is free, fast, and customized just for you!




Already a member?

Sign In Now »